(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-0.88%) $81.21
(-2.06%) $1.950
(-0.18%) $2 298.70
(-0.03%) $26.65
(-0.37%) $944.70
(0.11%) $0.938
(0.23%) $11.12
(0.10%) $0.801
(0.00%) $93.45
Live Chart Being Loaded With Signals
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally...
Stats | |
---|---|
Šios dienos apimtis | 966 000 |
Vidutinė apimtis | 0.00 |
Rinkos kapitalizacija | 703.28B |
EPS | ¥0 ( 2024-02-12 ) |
Kita pelno data | ( ¥-12.48 ) 2024-05-08 |
Last Dividend | ¥50.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 83.43 |
ATR14 | ¥533 134 202 (0.23%) |
Tūris Koreliacija
Taisho Pharmaceutical Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Taisho Pharmaceutical Koreliacija - Valiuta/Žaliavos
Taisho Pharmaceutical Finansinės ataskaitos
Annual | 2022 |
Pajamos: | ¥301.38B |
Bruto pelnas: | ¥177.85B (59.01 %) |
EPS: | ¥231.72 |
FY | 2022 |
Pajamos: | ¥301.38B |
Bruto pelnas: | ¥177.85B (59.01 %) |
EPS: | ¥231.72 |
FY | 2022 |
Pajamos: | ¥268.20B |
Bruto pelnas: | ¥163.83B (61.09 %) |
EPS: | ¥161.12 |
FY | 2021 |
Pajamos: | ¥282.04B |
Bruto pelnas: | ¥175.99B (62.40 %) |
EPS: | ¥166.84 |
Financial Reports:
No articles found.
Taisho Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥50.00 (N/A) |
¥0 (N/A) |
¥50.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥50.00 | 2010-03-29 |
Last Dividend | ¥50.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 27 | -- |
Total Paid Out | ¥1 320.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.76 | -- |
Div. Sustainability Score | 7.14 | |
Div.Growth Potential Score | 2.76 | |
Div. Directional Score | 4.95 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8068.T | Ex Dividend Knight | 2024-01-30 | Semi-Annually | 0 | 0.00% | |
7350.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6590.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
5936.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
4617.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3852.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3093.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
1967.T | Ex Dividend Junior | 2024-03-18 | Annually | 0 | 0.00% | |
9531.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8424.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0263 | 1.500 | 9.47 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00838 | 1.200 | 9.72 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0104 | 1.500 | -0.996 | -1.494 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.19 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.04 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 87.55 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.572 | 1.000 | 3.80 | 3.80 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0590 | 1.000 | -0.819 | -0.819 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.319 | 0.800 | -1.209 | -0.967 | [0.5 - 2] |
Total Score | 7.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 83.52 | 1.000 | 1.665 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0104 | 2.50 | -0.640 | -1.494 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.166 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -24.40 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.197 | 1.000 | 7.58 | 0 | [0.1 - 0.5] |
Total Score | 2.76 |
Taisho Pharmaceutical
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.